[Singapore] - As soon as HSA approves, government will speed up the roll-out of Sinovac vaccines

Hong Kong COVID-19 vaccination drive struggles to gain public trust
Virus Outbreak Hong Kong Vaccines
A man receives a dose of the Sinovac Biotech COVID-19 vaccine at a community vaccination centre in Hong Kong, Feb 23, 2021. (File photo: Paul Yeung/Pool via AP)
25 Mar 2021 02:28PM
(Updated: 25 Mar 2021 02:53PM)
Bookmark
HONG KONG: Hong Kong's sudden suspension of a COVID-19 vaccine developed by Pfizer and BioNTech is another blow to a vaccination programme already struggling against a wall of public distrust.

Hong Kong on Wednesday suspended use of the Pfizer-BioNTech vaccine, distributed by Chinese pharmaceutical firm Fosun Pharma, after defective packaging such as loose vial lids and cracks on bottles were found in one of two batches of the vaccine.

READ: Hong Kong, Macau suspend Pfizer-BioNTech COVID-19 vaccine over 'flawed' vials
For now, Hong Kong residents can only get the Chinese-made Sinovac vaccine, which is reported to have an efficacy rate of 62 per cent, compared with Pfizer-BioNTech's 97 per cent.

Wariness towards the Sinovac shot has grown after seven people who were vaccinated with it died, though authorities say the deaths were not linked to the vaccine.

When the government launched the vaccination drive in February, 66-year-old Chan Yuet Lin was eager to get inoculated.

A mainland Chinese immigrant in the city, she hoped vaccination would help her eventually visit her family in the Chinese mainland, whom she had not seen since the pandemic began, without enduring onerous quarantines.

But after seeing reports on television that several people with chronic illnesses had died days after having the Sinovac vaccine, Chan decided against getting inoculated.

READ: Hong Kong probes death of man who received COVID-19 vaccine
"I have high blood pressure, high cholesterol and high blood sugar. Right now with my health condition I don't think I can get the shot, I will wait and see," she said, adding that she planned to seek her doctor's advice at her next appointment.

Since vaccinations began on Feb 26, about 5.7 per cent of Hong Kong's 7.2 million residents have gotten inoculated – a far cry from a goal of vaccinating 70 per cent.

Virus Outbreak Hong Kong Vaccine
FILE - In this Friday, Feb. 26, 2021 file photo, People line up to receive China's Sinovac COVID-19 vaccine at a community vaccination centre in Hong Kong, Feb 26, 2021. (File photo: AP/Kin Cheung)
The government has expanded the range of people who can get the shots, allowing those 30 and above after initially prioritising those 60 and older, and employees from essential industries. It is considering giving the shots to anyone older than 16.

Slow progress on vaccinations could slow the city's economic recovery. Hong Kong is still grappling with COVID-19 outbreaks and stringent social distancing measures that are especially hard on bars, restaurants and the tourism industry.

The jobless rate climbed to 7.2 per cent in February, the highest level since 2004.

READ: Hong Kong to spend US$15.4 billion to stabilise virus-ravaged economy
Hong Kong leader Carrie Lam and health officials are urging people to get vaccinated. They insist the shots, including the Sinovac vaccine, are safe.

Hong Kong, a former British colony, relies heavily on tourism but has been closed to foreign visitors since March last year. Lam has said social distancing precautions and border controls can only be relaxed after most people have gotten the shots.

"If we can't control the epidemic, there's nothing we can do about the economy," she told lawmakers last week.

Virus Outbreak Hong Kong Vaccine
Hong Kong Chief Executive Carrie Lam receives the second dose of the Sinovac COVID-19 vaccine in Hong Kong, Mar 22, 2021. (File photo: AP/Vincent Yu)
Hesitancy towards the vaccines partly reflects growing mistrust of the government, as Beijing has asserted growing influence following months of anti-government protests in 2019.

Authorities have arrested and jailed dozens of activists under a tough new national security law.

READ: Hong Kong leader praises China's plan to install 'patriots'
Some residents are worried by the seven deaths that occurred after Sinovac shots.

"According to the government, none of the deaths are related to the vaccine. Most of the patients had cardiovascular conditions, so there must be some association, but the government seems to be trying to dissociate it," said Belinda Lin, a Hong Kong resident in her 30s.

"It's an issue of responsibility, the willingness to take responsibility – I haven't seen this yet," said Lin, who does not plan to get the vaccine as she says there is a lack of studies showing long-term effects.

READ: HSA starts review of Sinovac COVID-19 vaccine
"From what we've seen in the news so far it seems like people have more side effects from the (Sinovac) vaccine that's less effective," said Agnes Wong, a sales executive in Hong Kong who also had no immediate plans to get vaccinated.

Unease over the vaccines, which were developed in under a year using varying levels of clinical trials, are not confined to Hong Kong.

In Europe, reports of problems with blood clotting following the AstraZeneca shot raised concerns. So have questions over some of AstraZeneca's clinical data.

READ: AstraZeneca COVID-19 vaccine 76% effective in updated US trial results
The number of people who have booked but failed to show up for their Sinovac vaccine appointments currently stands at around 20 per cent, up from about 11 per cent a week into the programme.

That compares with a 5 per cent no-show rate for the Pfizer-BioNTech shot before those were halted.

COVID-19 vaccinations in Hong Kong
People leave a vaccination centre after Hong Kong temporarily suspended COVID-19 vaccines from a single batch of Pfizer-BioNTech shots due to packaging defects, Mar 24, 2021. (Photo: REUTERS/Tyrone Siu)
Martin Wong, a professor at the Chinese University of Hong Kong, co-authored a survey published in January that showed only 37 per cent of Hong Kong residents were willing to get a COVID-19 vaccine.

He says the technology used, a manufacturer's track record and reports of side effects can all affect willingness to get the shots.

The government has advised people with chronic illnesses to ask their doctors before getting the COVID-19 vaccines. That can be difficult for many underprivileged Hong Kong seniors, said Ivan Lin from the rights advocacy group Society of Community Organisation.

"The public health system should be more proactive in providing advice," said Lin. "For many of these elderly, their long-term illnesses are taken care of by public hospitals where appointments take place every three months, so they are not able to get (timely) medical advice."

READ: China to issue visas to foreigners who have taken China-made COVID-19 jab
Policies that would reward people for getting vaccinated are essential, says Wong.

"New incentives may be required such as exemptions from certain travel bans or issuance of a certificate of vaccination that can be used for different purposes," he said.

FILE PHOTO: People receive a dose of the Sinovac Biotech's COVID-19 vaccine at a community vac
People receive a dose of the Sinovac COVID-19 vaccine at a community vaccination centre in Hong Kong, Feb 23, 2021. (File photo: Paul Yeung/Pool via REUTERS)
Lam, the city's leader, has said the government might consider such measures, such as relaxing certain social distancing restrictions. Hong Kong is also discussing with Chinese authorities easing restrictions for travellers who are vaccinated.

That might work for some.

Bilal Hussain, a doctoral student at the Hong Kong Polytechnic University, signed up to receive his first shot of the Sinovac vaccine after learning that China had eased its policy to allow foreign workers and their families to apply for visas into the country.

Hussain's wife and five-year-old son are in China. He has not seen them since January last year.

"I'm hoping that maybe in the near future, China will open up their borders for students who have been vaccinated," he said.
 
Hong Kong says initial investigation of BioNTech vaccines shows no 'obvious systemic factors'
People queue up at a vaccination centre after Hong Kong temporarily suspended coronavirus disease (COVID-19) vaccine from a single batch of Pfizer/BioNTech shots due to packaging defects, in Hong Kong, China March 24, 2021. REUTERS/Tyrone Siu
28 Mar 2021 08:49AM
Bookmark
HONG KONG: Hong Kong's government said an initial investigation by Germany's BioNTech and Fosun Industrial into its coronavirus vaccine did not show any "obvious systemic factors" during packaging after use of the vaccine was suspended in the city and neighbouring Macau this week.
Authorities on Wednesday (Mar 24) halted the use of a COVID-19 vaccine developed by BioNTech citing defective packaging, triggering confusion in inoculation centres across the city.
The suspension came as the Asian financial hub has faced a sluggish take-up of vaccines due to dwindling confidence in China's Sinovac vaccine and fears of adverse reactions.
In a statement published late on Saturday, the city's government said the investigation results did not rule out that the situation was "caused by environmental conditions during the long-haul transport process".
It was not related to the cold-chain and logistical management of the vaccine and random testing of intact vials delivered to Hong Kong did not uncover any issue of leakage, it said.
Both Fosun and BioNTech considered the vaccines to have no safety risks and people who have received them "do not need to worry", the government said.
The remaining part of the investigation will focus on "ascertaining the integrity of the intrinsic properties of the relevant batches of vaccine, and that the batches are safe for use".
The government said it was following up with Fosun and BioNTech to complete the investigation within a week to allow for a resumption of supplying the vaccines to the public.
The city started vaccinating residents with doses from Sinovac in February and began offering the one developed by BioNTech in March.
The BioNTech vaccine is distributed in Hong Kong and Macau via a partnership with China's Fosun Pharma, while BioNTech partners with Pfizer in markets outside greater China.
 
Tia gong US imposing rule that ppl vaccinated w China vaccine not recognise and cannot enter US. Likewise China will retaliate - non sinovac vaccine not recognised. Better vaccinate both. Double protection.
 
Tia gong US imposing rule that ppl vaccinated w China vaccine not recognise and cannot enter US. Likewise China will retaliate - non sinovac vaccine not recognised. Better vaccinate both. Double protection.

Better idea: regime change China (PRC) just like how the allied forces regime changed Nazi Germany. Find out what really happened in Wuhan... and you'll be one step closer to finding a safe and effective cure.

The way I see it, if you get infected in future after receiving the vaccines, they will blame it on 'virus mutations' and come up with annual 'booster shots'. You will need to 'update' your body's 'software' every year. :rolleyes:

Deaths and side effects: blame your health conditions or old age.
Get infected (test positive): blame virus mutations.

Heads you lose, tails they win. See how the scam works? :wink:

EsKkXrNXYAANIs7.jpg
 
Consent form for Covid vaccination in China.

They only vaccinate those 18-59 years old... the Sinkie Pioneers and Merdekans should feel very fortunate indeed. :biggrin:

At least they're honest about not having the data of the vaccine's effect on humans (paragraph in red box). Jab and pray. You die ur biz. :wink:

P5UKJoQ.jpg
 
Piss and poop really fucked up. Buy fake goods and expect warranty?
 
New Abu Dhabi plant to make COVID-19 vaccine from China's Sinopharm
A paramedic prepares a dose of Sinopharm's COVID-19 vaccine before administering it to a resident at a vaccination centre in Karachi, Pakistan, on Mar 22, 2021. (File photo: Reuters/Akhtar Soomro)
29 Mar 2021 02:14PM
Bookmark
DUBAI: A new factory in Abu Dhabi will start manufacturing a COVID-19 vaccine from Chinese pharmaceutical giant Sinopharm later this year under a joint venture between Sinopharm and Abu Dhabi-based technology company Group 42 (G42).
The project is an expansion of Chinese diplomacy in the Gulf region and helps the United Arab Emirates' quest to diversify its economy away from hydrocarbon production.

The plant, which is being built in the Khalifa Industrial Zone of Abu Dhabi (KIZAD), will have a production capacity of 200 million doses a year with three filling lines and five automated packaging lines, a statement from the joint venture said on Monday (Mar 29).
The vaccine will be called Hayat-Vax when manufactured in the UAE, but is the same inactivated vaccine from the Beijing Institute of Biological Product (BiBP), a unit of Sinopharm's China National Biotec Group (CNBG), that the UAE approved for general use in December.
Production of Hayat-Vax has already begun in the emirate of Ras Al Khaimah under a deal between G42 and Gulf Pharmaceutical Industries, the statement said. That production line has an initial capacity of 2 million doses per month.
The UAE, through G42, hosted phase three clinical trials of the Sinopharm vaccine from July, which later expanded to other countries in the region including Bahrain. The UAE approved the vaccine for frontline workers in September before making it available to the general public in December.

The deal was launched during a two-day visit to the UAE by Chinese Foreign Minister Wang Yi which ended on Sunday.
The joint venture also includes a purpose-built research and development hub for life sciences, biotechnology and vaccine production in KIZAD.
READ: Sinopharm needs trial results to decide if COVID-19 vaccine needs booster shot
READ: China donates 400,000 doses of Sinopharm COVID-19 vaccine to Niger


"Our joint venture is also actively looking to bring our capabilities to new markets around the world," G42 CEO Peng Xiao said.
"Thanks to the close collaboration with the UAE, Sinopharm's vaccine has been now administered to millions of people in the country, the region and the world," Sinopharm Chairman Liu Jingzhen said at a virtual launch also attended by UAE Foreign Affairs Minister Sheikh Abdullah bin Zayed Al Nahyan.
The UAE has said its trials showed the vaccine has 86 per cent efficacy, while Sinopharm reports 79.34 per cent efficacy based on interim results.
Some people in the UAE failed to develop sufficient antibodies after a second dose of the Sinopharm vaccine and were given a third dose, the UAE health ministry said this month. It said the number was "minimal" compared to the number of vaccines administered.
On Sunday, a Sinopharm executive said the company will need to assess results from overseas phase three clinical trials to decide whether its two-shot vaccine should be followed by a booster shot.
 
WHO experts say Chinese jabs show 'safety', but data lacking - The Online Citizen Asia
WHO vaccine experts said Wednesday that an interim analysis of clinical trial data from two Chinese COVID-19 vaccines showed they demonstrated “safety and good efficacy”, but that more data was needed.
The Chinese firms Sinovac and Sinopharm, whose Covid jabs are already being used in several countries, have submitted data in applications for the World Health Organization’s emergency use listing (EUL) green light.
The UN health agency’s Strategic Advisory Group of Experts on Immunization (SAGE) said it had reviewed the data provided so far, and that both vaccines “demonstrated safety and good efficacy against symptomatic COVID-19 disease”.
However, it warned, “both vaccines lacked data in older age groups and in persons with co-morbidities,” meaning other medical conditions.
“Post-introduction vaccine effectiveness and safety studies will be needed to address the impact on those sub-populations,” SAGE said in a list of highlights published after a meeting last week to discuss developments on vaccines against a range of diseases.
The two vaccines are among four homegrown jabs that have been approved by Chinese regulators so far, but SAGE pointed out that neither had yet received authorisation by what the WHO considers “a stringent regulatory authority”.
SAGE, which advises the WHO on immunisation policies, said it would hold off on issuing recommendations for how the two Chinese vaccines should best be used until after another expert panel rules on their EUL applications.
An emergency use listing by the WHO paves the way for countries worldwide to quickly approve and import a vaccine for distribution.
It also opens the door for the jabs to enter the Covax global vaccine-sharing scheme, which aims to provide equitable access to doses around the world and particularly in poorer countries.
“For now, we have information that these vaccines are safe, and that they are in the process of defining their final analysis to show the efficacy that will be used for the emergency use listing approval,” SAGE chair Alejandro Cravioto told reporters.
“Once that is in place we will be able to make the necessary recommendations for its use.”
The WHO has so far granted emergency use listing to the COVID vaccines made by Pfizer/BioNTech, AstraZeneca/Oxford and Johnson & Johnson.
– AFP
 
Back
Top